Obinutuzumab for Rituximab-Resistant Nephrotic Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for nephrotic syndrome, particularly those resistant to Rituximab, are often ineffective and toxic, leading to a significant unmet clinical need for novel treatments that are more effective and less toxic.
Innovation Solution
Administering an effective amount of Obinutuzumab, a type 2 anti-CD20 monoclonal antibody, to treat or reduce the severity of nephrotic syndrome, including Rituximab-resistant cases, through various dosing regimens and combinations with standard-of-care treatments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Rituximab is used to treat nephrotic syndrome, then B-cell depletion is achieved, but treatment resistance develops and toxicity increases
Solution Approach 1:
The patent applies parameter changes by switching from Rituximab (a type 1 anti-CD20 antibody) to Obinutuzumab (a type 2 anti-CD20 antibody), which has different molecular characteristics including glycosylation patterns and epitope binding properties. This parameter change in the therapeutic agent enables effective B-cell depletion in Rituximab-resistant patients while maintaining a favorable toxicity profile
Solution Approach 2:
The patent uses Obinutuzumab as an intermediary therapeutic agent that mediates B-cell depletion through a different mechanism than Rituximab. This intermediary approach allows treatment of patients who have developed resistance to the original therapeutic agent while avoiding the cumulative toxicity associated with prolonged Rituximab use
2Reliability
If current therapies are administered daily for life, then disease control is maintained, but cumulative toxicity increases and efficacy diminishes
Solution Approach 1:
The patent implements periodic action by administering Obinutuzumab in discrete dosing regimens (e.g., intravenous infusions at specific intervals) rather than continuous daily administration. This periodic treatment approach maintains disease control while reducing cumulative toxicity and preventing the diminishing efficacy associated with long-term continuous therapy
Solution Approach 2:
The patent employs a disposable therapeutic approach using Obinutuzumab as a finite-duration treatment agent that achieves B-cell depletion and disease control without requiring lifelong administration. This contrasts with the continuous daily therapy paradigm and reduces long-term cumulative exposure to toxic effects
3Adaptability or versatility
If Rituximab-resistant nephrotic syndrome is treated with alternative therapies, then treatment options are expanded, but toxicity and side effects increase
Solution Approach 1:
The patent applies parameter changes by introducing Obinutuzumab with distinct molecular parameters (type 2 anti-CD20 classification, different glycosylation, alternative epitope binding) compared to Rituximab. This parameter differentiation provides expanded treatment options for Rituximab-resistant patients while maintaining a favorable side effect profile through the antibody's unique mechanism of action
Data Source
AI summary
Described herein are methods for treating nephrotic syndrome using an anti-CD20 antibody. In one embodiment, that anti-CD20 antibody is Obinutuzumab.